PAT-048

立即咨询

PAT-048

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

1359983-15-5

包装与价格：

包装	价格(元)
100mg	电议
250mg	电议
500mg	电议

产品介绍

PAT-048 是一种有效、选择性、可口服的自分泌运动因子 autotaxin 抑制剂，抑制 IL-6 mRNA 的表达，但在肺部纤维化模型中，对 autotaxin 蛋白水平和溶血磷脂酸 (LPA) 的产生无明显作用。在小鼠血浆中对 autotaxin 的 IC50 和 IC90 值分别为 20 nM 和 200 nM。在体内实验中，PAT-048 可降低皮肤纤维化。

Cas No.	1359983-15-5
Canonical SMILES	CCCN1N=CC(N2C3=C(C(SC4=CC=CC(C(O)=O)=C4F)=C2C)C=CC(Cl)=C3F)=C1
分子式	C₂₂H₁₈ClF₂N₃O₂S
分子量	461.91
溶解度	Soluble in DMSO
储存条件	Store at -20°C
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request
产品描述	PAT-048 is a potent, selective and orally active autotaxin inhibitor, inhibits IL-6 mRNA expression, but shows no effect on autotaxin protein and pulmonary lysophosphatidic acid (LPA) production in lung fibrosis model. PAT-048 shows an IC50 and IC90 of 20 nM and 200 nM for autotaxin in mouse plasma. PAT-048 reduces dermal fibrosis in vivo[1][2]. IC50: 20 nM (Autotaxin, in mouse plasma)[1] IC90: 200 nM (Autotaxin, in mouse plasma)[1] [1]. Castelino FV, et al. An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis. Arthritis Rheumatol. 2016 Dec;68(12):2964-2974. [2]. Black KE, et al. Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis. FASEB J. 2016 Jun;30(6):2435-50.